Streetbeat News

Analyst Ratings

LCTX

Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating on Lineage Cell Therapeutics (LCTX) and maintained a $6 price target.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 2:27 pm

META

Goldman Sachs analyst Eric Sheridan has maintained a Buy rating on Meta Platforms (NASDAQ:META) and increased the price target from $414 to $500.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 2:27 pm

MNDY

Piper Sandler analyst Brent Bracelin has reiterated an Overweight rating on Monday.Com (NASDAQ:MNDY) and maintained a $250 price target.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 2:20 pm

COHR

Needham analyst James Ricchiuti reiterated a Buy rating on Coherent (NYSE:COHR) and maintained a $52 price target.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 2:18 pm

REGN

BMO Capital analyst Evan David Seigerman maintains an Outperform rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raises the price target from $1055 to $1082.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 2:15 pm

ABBV

Raymond James analyst Gary Nachman maintains an Outperform rating on AbbVie (NYSE:ABBV) and raises the price target from $181 to $189 as of 4th February 2024.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 2:15 pm

RNR

BMO Capital analyst Michael Zaremski has maintained an Outperform rating on RenaissanceRe Holdings (NYSE:RNR) and increased the price target from $216 to $295.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 2:13 pm

SAIA

BMO Capital analyst Fadi Chamoun has maintained a 'Market Perform' rating on Saia (NASDAQ:SAIA) and increased the price target from $450 to $515.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 2:06 pm

RSKD

Riskified (NYSE:RSKD) has been analyzed by 4 analysts, showing a shift towards a more neutral stance in the last three months with an average 12-month price target of $5.00, down from $5.88. The company's financial indicators such as revenue growth, net margin, ROE, and ROA show positive performance, but it faces challenges in revenue growth compared to its peers. Riskified's low debt-to-equity ratio indicates a healthy balance between debt and equity.

Portfolio Pulse from Benzinga Insights

February 05, 2024 | 2:01 pm

EXPE

Expedia Group (NASDAQ:EXPE) received mixed ratings from 12 analysts, with a shift towards more bullish perspectives in recent evaluations. The average 12-month price target is now $164.00, up 27.13% from the previous $129.00, indicating a positive outlook. Analysts from firms like Oppenheimer, Goldman Sachs, and Mizuho have adjusted their ratings and price targets, reflecting changes in market dynamics and company performance. Despite positive revenue growth, Expedia faces challenges in net margin, ROE, and ROA, but has a healthy debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

February 05, 2024 | 2:00 pm